



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#6
11-13-02

In re application of : **Confirmation No. 5466**
Alfred SCHAUFLE : **Docket No. 2002-0094A**
Serial No. 10/054,889 : **Group Art Unit 1762**
Filed January 25, 2002 :

RECEIVED
NOV -8 2002
TC 1700 MAIL ROOM

A SUSPENSION COMPRISING
FIBRINOGEN, THROMBIN AND ALCOHOL,
A METHOD FOR PREPARING SUCH A
SUSPENSION, A METHOD FOR COATING
A CARRIER WITH SUCH A SUSPENSION,
A METHOD FOR DRYING A COATING OF
A CARRIER, AND A COATED COLLAGEN
SPONGE

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents,
Washington, DC 20231


Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicant requests consideration of [X] the references listed on attached form PTO-1449 and/or [] the additional information identified below in paragraph 3. A legible copy of each reference listed on the form PTO-1449 and each U.S. patent application listed below is enclosed, except a copy is not provided for each reference previously cited by or submitted to the Patent Office in prior parent application Serial No.

1a. [X] This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,



and thus no certification and/or fee is required.

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or

b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.


3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
 - b. ☒ a foreign patent office search report (in the English language) submitted herewith,
 - c. ☐ the concise explanation contained in the specification of the present application at page,
 - d. ☐ the concise explanation set forth in the attached English language abstract,
 - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☐ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Alfred SCHAUFLE

By




Nils E. Pedersen

Registration No. 33,145

Attorney for Applicant

NEP/krl
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
November 7, 2002

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975

| | | | | | | | |
|--|----|--|---------|---------------------------------|-------|--------------------------|-------------------------------|
| Sheet 1 of 1 | | | | | | | |
|  | | FORM PTO 1449 (modified) | | ATTY DOCKET NO. 2002-0094A | | SERIAL NO. 10/054,889 | |
| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO: November 7, 2002 | | | | APPLICANT Alfred SCHAUFLE | | | |
| | | | | FILING DATE January 25, 2002 | | GROUP 1762 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | AA | 4,606,337 | 8/1986 | Zimmermann et al. | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES NO |
| | AJ | 2668936 | 5/1992 | FR | | | |
| | AK | 99/56797 | 11/1999 | WO | | | |
| | AL | 99/59647 | 11/1999 | WO | | | |
| | AM | 93/19805 | 10/1993 | WO | | | |
| | AN | 97/28832 | 8/1997 | WO | | | |
| OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| | AO | PATENT ABSTRACTS OF JAPAN, vol. 1995, no. 6, July 31, 1995 & JP 07 059812 A (KOKEN CO LTD), March 7, 1995, abstract & DATABASE WPI, Week 199518, Derwent Publications Ltd., London, GB; AN 1995-135943, abstract. | | | | | |
| | AP | H. OSADA et al., "Clinical Evaluation of a Haemostatic and Anti-adhesion Preparation Used to Prevent Post-surgical Adhesion", JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, vol. 27, no. 5, 1999, pgs. 247-252, XP001085094, ISSN: 0300-0605, abstract. | | | | | |
| | AQ | | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.